Home » Topics » BioWorld Science

BioWorld Science
RSS

A-2342: a highly potent, selective, orally available NTCP inhibitor

Nov. 19, 2021

Discovery of novel APJ receptor agonist with promising activity in acute hemodynamic rat model

Nov. 19, 2021

Bexson expands ketamine patch pump program into depression

Nov. 19, 2021

Biopolar Hongye (Nantong) Pharmaceutical synthesizes JAK2 inhibitors

Nov. 19, 2021

Chinese researchers synthesize new phosphodiesterase PDE4 inhibitors

Nov. 19, 2021

Beijing Tide Pharmaceutical identifies GTPase KRAS inhibitors

Nov. 19, 2021

Betta Pharmaceuticals patents new compounds for cancer

Nov. 19, 2021

Hangzhou Innogate Pharma divulges SYK and JAK2 kinase inhibitors

Nov. 19, 2021

SGN-PDL1V, a PD-L1-directed ADC with activity in multiple tumor xenograft models

Nov. 19, 2021

Antibody-drug conjugate SGN-B7H4V shows promise in preclinical models of cancer

Nov. 19, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...